|Videos|September 21, 2022
Urology Times 50 Innovations Series: Sacral neuromodulation
Author(s)Urology Times staff
"[Sacral neuromodulation has] changed the treatment of OAB remarkably," says Howard B. Goldman, MD, FACS.
Advertisement
Urology Times® is celebrating its 50th anniversary in 2022. To mark the occasion, we are highlighting 50 of the top innovations and developments that have transformed the field of urology over the past 50 years. In this installment, Howard Goldman, MD, discusses the development of sacral neuromodulation as a treatment for overactive bladder (OAB). Goldman is a professor of urology and vice chair of the Glickman Urologic Institute at Cleveland Clinic.
Advertisement
Related to this article
The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
Positive safety and efficacy data from 4 clinical studies supported the CE marking.
The safety and efficacy of vibegron are supported by data from the phase 3 COURAGE and EMPOWUR trials.
EG110A is an investigational DNA medicine under development for neurogenic detrusor overactivity with urinary incontinence.
Advertisement
Advertisement
Trending on Urology Times
1
Aglatimagene besadenovec shows sustained immune remodeling in localized prostate cancer
2
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
3
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
4
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
5